Double-blind, randomized, placebo-controlled trial of allergen-specific immunotherapy with the major allergen Alt a 1.

导出原文传递

翻译打印收藏纠错

第一作者： Ana Isabel,Tabar

第一单位： Complejo Hospitalario de Navarra, Pamplona, Spain.

作者： Ana Isabel,Tabar ^[1] ; Luis,Prieto ^[2] ; Pilar,Alba ^[3] ; Antonio,Nieto ^[4] ; Mercedes,Rodríguez ^[5] ; Miguel,Torrecillas ^[6] ; Beatriz,Huertas ^[7] ; Elisa,Gómez ^[8] ; Francisco Javier,Fernández ^[9] ; Miguel,Blanca ^[10] ; David,Rodríguez ^[11] ; Ricardo,Palacios ^[12]

作者单位： Complejo Hospitalario de Navarra, Pamplona, Spain. ^[1] Hospital Universitario Dr. Peset, Valencia, Spain. ^[2] Hospital de Manises, Valencia, Spain. ^[3] Hospital Universitario La Fe, Valencia, Spain. ^[4] Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain. ^[5] Hospital Universitario Nuestra Señora del Perpetuo Socorro, Albacete, Spain. ^[6] Hospital del Sureste, Arganda del Rey, Madrid, Spain. ^[7] Hospital Universitario de Ciudad Real, Ciudad Real, Spain. ^[8] Hospital General, Universitario de Alicante, Alicante, Spain. ^[9] Hospital Regional Universitario Carlos Haya, Malaga, Spain. ^[10] Diater Laboratorios S.A., Leganés, Madrid, Spain. Electronic address: d.rodriguez@diater.com. ^[11] Diater Laboratorios S.A., Leganés, Madrid, Spain. ^[12]

关键词 Allergen immunotherapy Alt a 1 adults children clinical trial efficacy fungal allergy molecular immunotherapy purified allergen rhinoconjunctivitis safety subcutaneous immunotherapy